Eric Mann, MD
Ophthalmology · Dover, NJNPI 1508847930
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $441,264 of the $604,043 with a category attached, or 73.1%. 40 manufacturers reported payments, led by AbbVie at 53.2% of the total. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,656 payments — averaging $364.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$321K
- Bausch & Lomb Americas Inc.$138K
- Glaukos Corporation$19K
- Biotissue Holdings Inc.$17K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$16K
- Sun Pharmaceutical Industries Inc.$15K
- plus $77K from 34 others
Across 59 payments — averaging $4814.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$94K
- Dompe Farmaceutici S.p.a.$70K
- Biotissue Holdings Inc.$49K
- NEW World Medical,inc.$24K
- Bausch & Lomb Americas Inc.$19K
- Ocular Therapeutix, Inc.$12K
- plus $17K from 2 others
What the payments were for
- Consulting fees$77,03113%
- Speaking & faculty fees$441,26473%
- Travel & lodging$41,8427%
- Food & beverage$43,6237%
- Education$2380%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$235,754
- MIEBO$104,040
- XIIDRA$85,066
- VUITY$43,335
- RESTASIS$16,151
- CEQUA$14,154
- Travoprost Intraocular Implant - iDose$14,043
- DEXTENZA$13,220
- LOTEMAX SM$13,131
- RESTASIS MULTIDOSE$11,556
- ACTHAR$10,994
- Rocklatan$9,233
- Rhopressa$8,984
- enVista MX60 IOL$7,504
- AMINOGRAFT$4,013
- Clareon$3,739
- VYZULTA$3,649
- Oxervate$2,651
- TYRVAYA$2,400
- Kahook Dual Blade$2,297
How this compares
$604,043 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 22 | $1,184,571 |
| RestasisCyclosporine | 222 | $287,364 |
| XiidraLifitegrast | 105 | $160,205 |
| LumiganBimatoprost | 227 | $113,040 |
| XdemvyLotilaner | 33 | $61,433 |
| Cyclosporine | 88 | $57,173 |
| RocklatanNetarsudil Mesylat/Latanoprost | 75 | $55,451 |
| MieboPerfluorohexyloctane/Pf | 55 | $55,196 |
| CequaCyclosporine | 18 | $26,938 |
| VyzultaLatanoprostene Bunod | 54 | $23,764 |
| RhopressaNetarsudil Mesylate | 36 | $20,220 |
| Prednisolone Acetate | 439 | $19,787 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $18,713 |
| TyrvayaVarenicline Tartrate | 21 | $18,113 |
| Restasis MultidoseCyclosporine | 19 | $17,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $4,203 | $1,184,57122 claims |
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $321,113 | $442,834531 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $138,127 | $239,165214 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $8,586 | $75,671111 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,006 | $61,43333 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $15,446 | $26,93818 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $2,695 | $18,11321 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Besivance | $15,937 | $16,03567 claims |
| AlconSimbrinza | $7,549 | $7,01122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Dover
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
- Susan HughesCherry Hill$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.